ABSTRACT
Background:
Cough variant asthma is a prevalent condition among
children with
chronic cough, significantly impacting their
health and well-being.
Objective:
This study aimed to assess the impact of
spleen aminopeptide oral lyophilized
powder and
fluticasone/
salmeterol powder inhaler on pulmonary function and the
incidence of adverse reactions in
children with
cough variant asthma.
Methods:
A total of 60
children with
cough variant asthma admitted to the Pediatric Department of Cangzhou Central
Hospital between July 2019 and June 2020 were enrolled in the study. Using the random number table
method, they were assigned to either the
observation group or the
control group, with 30 cases in each group. The
control group received
treatment with
fluticasone/
salmeterol powder inhalers, while the
observation group received a combination of
fluticasone/
salmeterol powder inhalers and
spleen aminopeptide oral lyophilized
powder. After 8 weeks of
treatment, various clinical
parameters, including
forced vital capacity,
forced expiratory volume per second/
forced vital capacity, peak expiratory flow,
fractional exhaled nitric oxide (FeNO),
interleukin-4 (
IL-4),
IL-10,
eosinophils in
induced sputum, and
serum CD4+ and CD8+ levels, were compared between the two groups.
Results:
The
observation group exhibited a higher total effective rate of
clinical efficacy compared to the
control group [90.00% vs. 63.33%; OR (95% CI) 3.00 (1.01-8.92), P = .048)]. After 8 weeks, the
observation group demonstrated higher levels of
forced vital capacity,
forced expiratory volume per second/
forced vital capacity, peak expiratory flow [OR (95% CI) 0.48 (0.26-0.88), P = .017; OR (95% CI) 0.29 (0.14-0.57) 2.57 (1.46-4.52) 0.33 (0.16-0.70), P = .000, .001, .003],
IL-10 [OR (95% CI) 0.29 (0.14-0.57), P = .000], and lower levels of FeNO [OR (95% CI) 0.48 (0.26-0.88), P = .017],
IL-4, and
eosinophils [OR (95% CI) 2.57 (1.46-4.52) 0.33 (0.16-0.70), P = .001, .003] compared to the
control group (P < .05). Furthermore, the
observation group exhibited higher levels of CD4+ and CD4+/CD8+ compared to the
control group [OR (95% CI) 0.41 (0.25-0.67) 0.33 (0.20-0.56) 1.73 (1.18-2.55), P = .000, .000, .001]. Computed
tomography measurements revealed significantly lower
airway wall thickness,
basement membrane thickness, and total
airway wall area in the
observation group compared to the
control group [OR (95% CI) 0.18 (0.10-0.33) 0.23 (0.13-0.41) 0.28 (0.15-0.51), P = .000, .000, .000]. The
incidence of adverse reactions did not significantly differ between the groups (6.67% vs. 3.33%; P > .05).
Conclusion:
The combination
treatment of
spleen aminopeptide oral lyophilized
powder and
fluticasone/
salmeterol powder inhaler effectively improves
lung function, FeNO levels, and
airway inflammation, while enhancing cellular and humoral immune function in
children with
cough variant asthma. These findings have significant clinical implications and warrant further promotion and application of this
treatment approach.